Skip to main content

Press Releases

Recent Press Releases

Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC
Hepion Pharmaceuticals Announces Reverse Stock Split
Hepion Pharmaceuticals Announces $9.0 Million Public Offering
Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.
Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson’s Disease Study Group
Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger
Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
Hepion Pharmaceuticals to Present at NASH-TAG 2024
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease
Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference
New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening Program
Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer
Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis
Hepion Pharmaceuticals Announces Management Changes
Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023
Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat
Hepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical Sciences
Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers
Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split
Hepion Pharmaceuticals to Present Data on Synergistic Effects of Rencofilstat with Anti-PD1 at AACR 2023
Hepion Pharmaceuticals Expands SAB with Appointments of Four Liver Disease KOLs
Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug Development
Hepion Pharmaceuticals to Deliver Updates on Ongoing Phase 2 NASH Clinical Program with Rencofilstat at 6th Global NASH Congress
EPO Decision to Grant European Patent for Rencofilstat Further Strengthens Hepion’s Patent Portfolio
Hepion Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell on February 10, 2023
Anti-Cancer Potential of Rencofilstat Expanded with Results from Preclinical Multiple Myeloma Studies
Presentation of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors
Hepion Pharmaceuticals Receives $3.2 Million in Aggregate Non-Dilutive Funding
Hepion Pharmaceuticals to Present Phase 2a Rencofilstat Multiomics Data at NASH-TAG 2023
Hepion Pharmaceuticals, Inc. Granted 180-day Extension by Nasdaq to Meet the Minimum Bid Price Requirements
Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial
Hepion Pharmaceuticals to Present Rencofilstat’s Poly-Indication Potential at the 6th Annual Antifibrotic Drug Development Summit
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
Hepion Pharmaceuticals to Present Two Posters at Upcoming AASLD The Liver Meeting® 2022
Hepion Pharmaceuticals Announces Publication of Phase 2a ‘AMBITION’ Clinical Trial Results
Hepion Pharmaceuticals Announces Publication of Food Effect Study with Rencofilstat
Hepion Pharmaceuticals to Participate in the ThinkEquity Conference
Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
Upcoming Presentation at Joint Meeting of ISBRA and ESBRA to Highlight Potential of Hepion Pharmaceutical’s Rencofilstat to Treat Alcohol-Related Liver Disease
Hepion Pharmaceuticals Announces Initiation of Dosing in Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial
Hepion Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Hepion Pharmaceuticals Announces Initiation of Phase 2b ‘ASCEND-NASH’ Trial
Hepion Pharmaceuticals Announces Further Adjournment of Annual Meeting of Stockholders
Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders
Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellular Carcinoma
Hepion Pharmaceuticals to Present Five Posters at EASL International Liver Congress™ 2022
Hepion Pharmaceuticals Appoints Accomplished Life Sciences Industry Veteran, Dr. Launa J. Aspeslet, as Chief Operating Officer
Hepion Pharmaceuticals Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual Meeting
Hepion Pharmaceuticals Highlights Upcoming Phase 2 Clinical Trials of Rencofilstat at 5th Global NASH Congress
Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial
Hepion Pharmaceuticals Appoints World-Renowned Hepatologist, Dr. Eddie C. Cheung, to Lead the Company’s Strategic Medical Affairs in Asia
Hepion Pharmaceuticals to Present at BIO CEO & Investor Conference
Hepion Pharmaceuticals’ Rencofilstat, in Combination with an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity in a Nonclinical Liver Cancer Study
Hepion Pharmaceuticals Announces Death of Director, Thomas Adams
Hepion Pharmaceuticals Announces USAN Selection of “Rencofilstat” as Nonproprietary Name for CRV431
Hepion Pharmaceuticals Announces Participation in the H.C. Wainwright BioConnect Conference
Hepion Pharmaceuticals to Present Clinical Data at NASH-TAG Conference
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer
Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH
Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study
Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021
Anti-Cancer Mechanism of Hepion Pharmaceuticals’ CRV431 Highlighted in Scripps Research Institute Poster at AASLD, The Liver Meeting® 2021
Hepion Pharmaceuticals to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference
All Endpoints Met in Hepion Pharmaceuticals’ Drug-Drug Interaction Study with CRV431
Additional Data from Hepion Pharmaceuticals’ Phase 2a ‘AMBITION’ Trial Further Strengthens CRV431 Clinical Profile and Paves Way for Initiation of Phase 2b ‘ASCEND-NASH’ Clinical Program
Hepion Pharmaceuticals Schedules Conference Call to Review Data from Phase 2a ‘AMBITION’ Clinical Trial of CRV431 in NASH
Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders
Hepion Pharmaceuticals Announces Positive Topline Data from Phase 2a ‘AMBITION’ NASH Trial; All Primary Endpoints Achieved
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting
Hepion Pharmaceuticals to be Added to the Russell Microcap® Index
Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a ‘AMBITION’ Clinical Trial of CRV431 for the Treatment of Advanced NASH
Hepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th Global NASH Congress
DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical’s Lead Drug, CRV431
Hepion Pharmaceuticals Announces Presentation and Panel Participation at the Benzinga Global Biotech Small Cap Conference
Hepion Pharmaceuticals to Present on CRV431 and AI-POW(TM) at NASH-TAG 2021
Hepion Pharmaceuticals, Inc. Announces Closing of Public Offering
Hepion Pharmaceuticals Announces Pricing of Public Offering
Hepion Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
Hepion Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference
Hepion Pharmaceuticals to Participate in Upcoming January Virtual Investor Conferences
Hepion Pharmaceuticals Announces Positive Top Line Data for Low Dose CRV431 in Phase 2a ‘AMBITION’ Clinical Trial for Treatment of Advanced NASH
Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a ‘AMBITION’ Clinical Trial for Treatment of Advanced NASH
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 for COVID-19
Hepion Pharmaceuticals Completes 75 mg CRV431 Dosing, Initiates 225 mg Dosing in Phase 2a ‘AMBITION’ Clinical Trial for NASH
Hepion Pharmaceuticals’ CRV431 Demonstrates Additional Potential Advantage in Liver Disease